Abstract
Tigecycline's MIC 90 of 1 mcg/mL was comparable to imipenem and 2 to 64 fold better than the beta-lactams, betalactam/beta-lactamase inhibitor combinations and levofloxacin against all Enterobacteriaceae tested. Tigecycline demonstrated potent in vitro activity against both ESBL and non-ESBL producing E. coli, K. oxytoca and K. pneumoniae. Tigecycline showed potent activity against A. baumannii with low MIC 50/90 values of 0.25 and 1 mcg/mL, respectively. Tigecycline's limited activity against P. aeruginosa is similar to other tetracyclines and their analog derivatives. Tigecycline showed potent inhibitory activity against S. aureus regardless of methicillin-resistant phenotype. At 0.12 mcg/mL tigecycline had the lowest MIC 90 value of all comparative agents against both vancomycinsensitive and -resistant strains of E. faecium and E. faecalis. Tigecycline presented a MIC 90 value of 0.5 mcg/mL against H. influenzae and was unaffected by the presence of beta-lactamase. The in vitro activity of tigecycline in this study suggests that tigecycline is a promising compound in the treatment of serious infections caused by the most commonly encountered nosocomial and community acquired pathogens. BACKGROUND
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
